Anti-CD19 IL-10 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
Status:
RECRUITING
Trial end date:
2027-01-06
Target enrollment:
Participant gender:
Summary
This study is a single-center, open-label, single-arm, dose-escalation trial. The aim of this study is to investigate the safety and efficacy of anti-CD19 IL-10 CAR-NK cells in patients with refractory/relapsed autoimmune diseases, including systemic sclerosis, idiopathic inflammatory myositis, ANCA associated vasculitis, sjogren syndrome, and antiphospholipid syndrome.
Phase:
NA
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University